UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

Developing histone deacetylase inhibitors as anti-cancer therapeutics

Current medicinal chemistry, 2011-04, Vol.18 (11), p.1658

2011

Volltextzugriff (PDF)

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

Annals of oncology, 2017-02, Vol.28 (2), p.354-361

2017

Volltextzugriff (PDF)

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Annals of oncology, 2018-10, Vol.29, p.viii17-viii18

2018

Volltextzugriff (PDF)

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2017-09, Vol.28, p.v617-v617

2017

Volltextzugriff (PDF)

The integrin αvβ6 is a promising therapeutic target for treating PDAC

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2016-06, Vol.16 (3), p.S6-S6

2016

Volltextzugriff (PDF)

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

European journal of cancer (1990), 2013-03, Vol.49 (4), p.782-789

2013

Volltextzugriff (PDF)

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.189-189

2012

Volltextzugriff (PDF)

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

European journal of cancer (1990), 2012-11, Vol.48, p.188-188

2012

Volltextzugriff (PDF)

599 Effect of Food On Relative Bioavailability of E7820 in Cancer Patients

European journal of cancer (1990), 2012-11, Vol.48, p.184-184

2012

Volltextzugriff (PDF)

6590 POSTER Phase Ma Study of TP300 as 1st-line Monotherapy in Patients With Advanced Gastric (GC) or Gastro-oesophageal Junction (GOJ) Carcinoma

European journal of cancer (1990), 2011, Vol.47, p.S468-S469

2011

Volltextzugriff (PDF)

mTOR signaling is a promising therapeutic target in a subset of human pancreatic ductal adenocarcinomas

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2013-01, Vol.13 (1), p.e8-e8

2013

Volltextzugriff (PDF)

CXCR2 inhibition protects against chronic pancreatitis in a murine model

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2013-01, Vol.13 (1), p.e5-e5

2013

Volltextzugriff (PDF)

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Annals of oncology, 2016-12, Vol.27 (12), p.2268-2274

2016

Volltextzugriff (PDF)

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

Annals of oncology, 2023-10, Vol.34, p.S667-S668

2023

Volltextzugriff (PDF)

LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes

Annals of oncology, 2023-10, Vol.34, p.S1339-S1339

2023

Volltextzugriff (PDF)

Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

European journal of cancer (1990), 2022-10, Vol.174, p.S82-S83

2022

Volltextzugriff (PDF)

549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)

Annals of oncology, 2021-09, Vol.32, p.S610-S610

2021

Volltextzugriff (PDF)

527P Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)

Annals of oncology, 2021-09, Vol.32, p.S594-S594

2021

Volltextzugriff (PDF)

475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)

Annals of oncology, 2021-09, Vol.32, p.S568-S568

2021

Volltextzugriff (PDF)

354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)

Annals of oncology, 2022-09, Vol.33, p.S697-S698

2022

Volltextzugriff (PDF)

139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma

Annals of oncology, 2021-12, Vol.32, p.S1438

2021

Volltextzugriff (PDF)

91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein

Annals of oncology, 2021-12, Vol.32, p.S1411-S1413

2021

Volltextzugriff (PDF)

525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors

Annals of oncology, 2021-09, Vol.32, p.S592-S592

2021

Volltextzugriff (PDF)

FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

Annals of oncology, 2017-09, Vol.28, p.v427-v427

2017

Volltextzugriff (PDF)

Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors

Annals of oncology, 2017-09, Vol.28, p.v128-v128

2017

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(67)
Dissertationen
(1)

Sprache

Englisch
(68)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Oncology
(18)
Female
(15)
Aged
(14)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Middle Aged
(14)
Male
(13)
Adult
(11)
Pharmacology. Drug Treatments
(10)
Antineoplastic Agents
(7)
Hematology, Oncology And Palliative Medicine
(7)
Treatment Outcome
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Chemotherapy
(5)
Tumors
(5)
Aged, 80 And Over
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Developing histone deacetylase inhibitors as anti-cancer therapeutics

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

The integrin αvβ6 is a promising therapeutic target for treating PDAC

A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

599 Effect of Food On Relative Bioavailability of E7820 in Cancer Patients

6590 POSTER Phase Ma Study of TP300 as 1st-line Monotherapy in Patients With Advanced Gastric (GC) or Gastro-oesophageal Junction (GOJ) Carcinoma

mTOR signaling is a promising therapeutic target in a subset of human pancreatic ductal adenocarcinomas

CXCR2 inhibition protects against chronic pancreatitis in a murine model

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma

LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes

Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors

549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)

527P Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)

475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)

354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)

139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma

91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein

525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors

FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors

Suchergebnisse filtern